NeuroSearch (NEUR) will present at the Bear Stearns Healthcare Conference to be held from 10-11 September in New York. The presentation will be held by Flemming Pedersen, CEO, and is scheduled for: Monday 10 September 2007 from 8:30 am to 8:55 am A PowerPoint version of the presentation will be accessible on our website www.neurosearch.com just prior to the presentation at the conference. Contact person: Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate Communications - telephone: +45 4460 8212 or +45 4017 5103 NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX Nordic Exchange Copenhagen A/S. Our core business covers the development of novel drugs, based on a broad and well-established drug discovery platform focusing on ion channels and CNS disorders. A substantial part of the company's activities are partner financed through a broad alliance with GlaxoSmithKline (GSK) and collaborations with among others Abbott and Astellas. The drug pipeline comprises 11 clinical (Phase I-III) development programmes: ACR16 in Huntington's disease (Phase III preparation), tesofensine in obesity/type 2 diabetes (Phase II), NS2359 in depression (Phase II) and ADHD (Phase II) in partnership with GSK, NS1209 in epilepsy and pain (Phase II), ABT-894 in ADHD (Phase II) and pain (Phase I) in partnership with Abbott, ACR16 in schizophrenia (Phase I) in partnership with Astellas, ACR325 in Parkinson's disease and bipolar disorder (Phase I) and ABT-107 as well as ABT-560 for the treatment of various CNS diseases - both (Phase I) in collaboration with Abbott. In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.
NeuroSearch to present at the Bear Stearns Healthcare Conference in New York
| Source: NTG Nordic Transport Group A/S